Skip to content
Mesa PRP Label Guide
Medical claims, translated one verb at a time

Mesa PRP Label Guide

How to read a PRP claim without getting lost

This page helps you tell a useful PRP claim from a broad promise. We'll explain a fair comparison and give you an example of a good answer. You won't need to sort through research language.

A useful claim names the joint and the result

PRP is short for platelet-rich plasma, a shot made after a clinic spins your blood. Spinning separates platelets for the syringe, while these small blood cells help stop bleeding and send signals used in early repair. The shot goes into the sore joint or tendon to support those signals, though it may not bring relief.

In a fair study, some people receive PRP while others get salt water or different care, and both groups are checked later using identical questions about pain and movement. A clinic's success rate doesn't give you that comparison. Without it, improvement might have come from rest, time, or other care.

A good answer includes hopeful and doubtful results

A clear answer might say some reviews found PRP ahead of cortisone later. It should also mention a large knee study that found no pain difference from salt water at 12 months. You'll then have both sides, because a promise that leaves out the doubtful result isn't complete.

Your own joint still needs an exam because soreness has many causes. Tell the clinician what brings the ache on and what brings relief. You may ask which study best matches the cause found during your exam, and the answer shouldn't claim one treatment suits every joint.

When soreness persists, the visit should begin with an exam

If the ache hasn't eased, QC Kinetix offers biologic therapies. This means care using material from your blood, prepared at the clinic as one of its non-surgical choices. The clinicians called medical providers review your health and examine the joint before discussing PRP because they can't know whether it fits earlier.

You can ask about expected soreness, daily activity, and symptoms that need help. Ask which exam result would make PRP a poor choice. A useful reply may point to another treatment, yet you'll still leave with a clearer answer about the ache.

Sources

  1. FDA states verbatim of stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming cells from umbilical cord blood, approved only for disorders of blood production, and there are no FDA-approved exosome products. PRP is a different product from all of these and the categories must not be blurred in either direction.

    U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

  2. In January 2025 the FTC and the Georgia Attorney General obtained federal court orders permanently BANNING the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy, plus $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that the defendants published false and misleading advertisements about the efficacy and approval of stem cell injections for conditions including osteoarthritis; the affiliated clinic had charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

    Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

  3. A web surveillance study of regenerative medicine clinics in the US-Mexico border region found 99.1% of the clinic websites mentioned no affiliation with an academic institution or other overt token of scientific legitimacy, 67.3% claimed autologous tissue as the source of treatment, and most did not specify the route of administration. Of the Tijuana clinics identified, 13 claimed licensing but only one matched available licensing records.

    Chavez J, Shah NA, Ruoss S, et al. — Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study. Stem Cell Research & Therapy, 2021. DOI: 10.1186/s13287-021-02254-4.

  4. A meta-analysis of 73 articles covering 5,895 patients quantified the PLACEBO response to intra-articular injection in knee osteoarthritis: statistically and clinically significant improvements in pain, function and quality of life at 1, 3 and 6 months, with responder rates above 50% at each of those points, declining by 12 months. The placebo response was stronger in trials with more female participants and in more recently published trials. This is why an uncontrolled 'our patients improved' figure carries almost no information.

    Previtali D, Boffa A, Di Laura Frattura G, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.

  5. The Cochrane review of STEM CELL injections for knee osteoarthritis concluded that on low-certainty evidence they may slightly improve pain and function, with uncertainty about effects on quality of life, treatment success and structural progression, and uncertainty about safety. This matters on a PRP site because 'stem cell therapy' is routinely used as a marketing label for PRP; they are different products with different evidence and PRP must never be described as a stem cell treatment.

    Whittle SL, Johnston RV, McDonald S, et al. — Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

  6. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

    Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

A clinic can examine soreness that keeps returning

When the ache hasn't settled, QC Kinetix has regenerative treatment options. In plain words, this is non-surgical care made at the clinic with material drawn from your blood. One choice is PRP, or platelet-rich plasma, prepared by spinning the blood and saving fluid with many platelets. Those cells help a cut clot and send repair signals.

The clinicians serving as medical providers examine you and consider your health and earlier care first. Most Mesa readers use Chandler. North and northeast Mesa may find Scottsdale easier, and you can call (602) 837-PAIN when you're ready to talk.

Book a free consultation